Puneet Souda
Stock Analyst at Leerink Partners
(1.96)
# 3,128
Out of 5,124 analysts
219
Total ratings
48.31%
Success rate
-0.8%
Average return
Main Sectors:
Stocks Rated by Puneet Souda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Maintains: Outperform | $115 → $155 | $102.14 | +51.75% | 7 | Dec 15, 2025 | |
| TMO Thermo Fisher Scientific | Maintains: Outperform | $545 → $580 | $579.45 | +0.09% | 20 | Oct 22, 2025 | |
| HOLX Hologic | Maintains: Market Perform | $70 → $78 | $74.49 | +4.71% | 8 | Oct 21, 2025 | |
| CYRX Cryoport | Upgrades: Outperform | $16 | $9.60 | +66.67% | 7 | Aug 6, 2025 | |
| MASS 908 Devices | Upgrades: Outperform | $12 | $5.25 | +128.57% | 7 | Aug 5, 2025 | |
| QTRX Quanterix | Downgrades: Market Perform | $12 → $8 | $6.36 | +25.79% | 12 | Apr 30, 2025 | |
| NEO NeoGenomics | Downgrades: Market Perform | $25 → $9 | $11.76 | -23.47% | 10 | Apr 30, 2025 | |
| MYGN Myriad Genetics | Downgrades: Market Perform | $30 → $21 | $6.15 | +241.46% | 7 | Dec 9, 2024 | |
| VCYT Veracyte | Maintains: Outperform | $35 → $40 | $42.10 | -4.99% | 14 | Oct 17, 2024 | |
| NTRA Natera | Maintains: Outperform | $140 → $150 | $229.09 | -34.52% | 7 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $325 → $375 | $379.83 | -1.27% | 15 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $35 | $38.90 | -10.03% | 11 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $170 → $145 | $136.07 | +6.56% | 19 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $300 | $228.92 | +31.05% | 1 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $249 → $250 | $131.16 | +90.61% | 19 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $110 | $58.81 | +87.04% | 6 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $75 | $101.56 | -26.15% | 16 | Jan 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $230 → $200 | $163.86 | +22.06% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $3.42 | +426.32% | 6 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $1.85 | +224.32% | 1 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $45 → $30 | $31.72 | -5.42% | 6 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $87 | $47.11 | +84.67% | 13 | May 5, 2022 |
Guardant Health
Dec 15, 2025
Maintains: Outperform
Price Target: $115 → $155
Current: $102.14
Upside: +51.75%
Thermo Fisher Scientific
Oct 22, 2025
Maintains: Outperform
Price Target: $545 → $580
Current: $579.45
Upside: +0.09%
Hologic
Oct 21, 2025
Maintains: Market Perform
Price Target: $70 → $78
Current: $74.49
Upside: +4.71%
Cryoport
Aug 6, 2025
Upgrades: Outperform
Price Target: $16
Current: $9.60
Upside: +66.67%
908 Devices
Aug 5, 2025
Upgrades: Outperform
Price Target: $12
Current: $5.25
Upside: +128.57%
Quanterix
Apr 30, 2025
Downgrades: Market Perform
Price Target: $12 → $8
Current: $6.36
Upside: +25.79%
NeoGenomics
Apr 30, 2025
Downgrades: Market Perform
Price Target: $25 → $9
Current: $11.76
Upside: -23.47%
Myriad Genetics
Dec 9, 2024
Downgrades: Market Perform
Price Target: $30 → $21
Current: $6.15
Upside: +241.46%
Veracyte
Oct 17, 2024
Maintains: Outperform
Price Target: $35 → $40
Current: $42.10
Upside: -4.99%
Natera
Oct 17, 2024
Maintains: Outperform
Price Target: $140 → $150
Current: $229.09
Upside: -34.52%
Aug 1, 2024
Upgrades: Outperform
Price Target: $325 → $375
Current: $379.83
Upside: -1.27%
Jun 5, 2023
Maintains: Outperform
Price Target: $50 → $35
Current: $38.90
Upside: -10.03%
May 24, 2023
Maintains: Outperform
Price Target: $170 → $145
Current: $136.07
Upside: +6.56%
May 1, 2023
Initiates: Outperform
Price Target: $300
Current: $228.92
Upside: +31.05%
Feb 8, 2023
Maintains: Outperform
Price Target: $249 → $250
Current: $131.16
Upside: +90.61%
Feb 3, 2023
Maintains: Outperform
Price Target: $125 → $110
Current: $58.81
Upside: +87.04%
Jan 12, 2023
Maintains: Outperform
Price Target: $70 → $75
Current: $101.56
Upside: -26.15%
Jan 6, 2023
Maintains: Outperform
Price Target: $230 → $200
Current: $163.86
Upside: +22.06%
Jan 6, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $3.42
Upside: +426.32%
Nov 29, 2022
Initiates: Outperform
Price Target: $6
Current: $1.85
Upside: +224.32%
Nov 21, 2022
Maintains: Market Perform
Price Target: $45 → $30
Current: $31.72
Upside: -5.42%
May 5, 2022
Maintains: Outperform
Price Target: $85 → $87
Current: $47.11
Upside: +84.67%